OUR MISSION IS TO CURE GLAUCOMA AND RESTORE VISION THROUGH INNOVATIVE RESEARCH

CELEBRATING OUR CATALYST FOR A CURE CONSORTIA

THE CURE IS IN SIGHT.
Our mission is to cure glaucoma and restore vision through innovative research.

Gratitude: Thanks to your generosity in 2022, scientists funded by Glaucoma Research Foundation made critical discoveries. And patients and caregivers connected with informative print materials, accessible online resources, and inclusive events.

Ambitious Goals: Our Board of Directors has finalized a new strategic plan that reinforces our mission. Key elements include accelerating innovative research, increasing patient-centered activities, and raising glaucoma awareness.

Collaboration: We now have two Catalyst for a Cure initiatives in progress simultaneously. Launched in July, the Melza M. and Frank Theodore Barr Catalyst for a Cure to Prevent and Cure Neurodegeneration unites scientists in an unprecedented search for solutions to glaucoma, Alzheimer's, and other neurodegenerative diseases. Ongoing since 2019, the Steven and Michele Kirsch Catalyst for a Cure Vision Restoration Initiative has made enormous strides that could soon result in the ability to protect, preserve, and even regenerate retinal nerve cells.

Community: An updated website strengthens our global reach by providing comprehensive, accurate, helpful online information about glaucoma. Although we have returned to in-person events, including Glaucoma 360 and our Glaucoma Patient Summit, we continue to offer virtual activities to inform, inspire, and support our community.

Thank you for your commitment to our vision of a future free from glaucoma.

Thomas M. Brunner
President and CEO

Andrew G. Iwach, MD
Chair, Board of Directors
New Shaffer Grants Reveal Promising Research Directions

2022 SHAFFER GRANTS FOR INNOVATIVE GLAUCOMA RESEARCH

Glaucoma Research Foundation has funded more than 290 Shaffer Grants. These one-year research grants provide $50,000 in seed money for creative projects that show strong potential for impact on glaucoma.

The 2022 Shaffer Grants were made possible through leadership gifts from the Frank Stein and Paul S. May Grants for Innovative Glaucoma Research, Bob and Birdie Feldman & Giving Tuesday contributions, Tania and Michael Stepanian, the Dr. Henry A. Sutro Family Grant for Research, and the Dr. Miriam Yelsky Memorial Research Grant.

KUN-CHE CHANG, PHD
University of Pittsburgh

“The success of this project would lead to a new avenue for preserving vision by promoting retinal ganglion cell survival and axon regeneration. These findings will establish new therapeutic strategies with a gene therapy that’s effective at reversing degeneration in glaucoma.”

M. ELIZABETH FINI, PHD
Tufts University

“Study results will provide the preliminary data needed to further validate our hypothesis for the mechanism of steroid-induced ocular hypertension. The ultimate goal is to learn whether pharmaceutical glucocorticoids directly stimulate expression of a specific gene that is responsible for steroid-induced glaucoma.”

SIDNEY KUO, PHD
University of Minnesota

“We hypothesize that IOP-induced changes to the physical structure of Müller glial cells early in disease onset contribute importantly to the eventual death of retinal ganglion cells. By identifying early pathological events in Müller cells, our goal is to provide new insight into ways to diagnose and treat glaucoma before retinal ganglion cells are lost.”

MYOUNGSUP SIM, PHD
Duke University

“Recent studies have shown a potential role of nitric oxide in lowering IOP. Successful results from this study will provide an upstream target molecule that can regulate endogenous nitric oxide production and advance current nitric oxide-based glaucoma drugs to treat glaucoma patients more safely.”

BRIAN SOETIKNO, MD, PHD
Stanford University

“This study will provide insight into whether we can detect retinal ganglion cell damage at ultra-high resolution in the inner plexiform layer. Ultimately, visible-light OCT (a new type of optical coherence tomography imaging device) could offer a new imaging biomarker for detecting glaucoma early and monitoring its progression.”

QING WANG, MD, PHD
Columbia University

“Astrocytes are thought to play both neuroprotective and neurotoxic roles in complex neurodegenerative diseases, such as glaucoma and Alzheimer’s. Our study will provide important molecular information and tools for manipulating optic nerve head astrocytes to understand and treat glaucoma.”
Total revenue for the fiscal year ended June 30, 2022, was $5.3 million. GRF continues to have a strong balance sheet, finishing the year with total assets of $13 million. We’re proud to have earned Charity Navigator’s highest 4-star rating for a sixth consecutive year, recognizing our organization’s strong financial health and commitment to accountability and transparency. Our audited financial reports are posted on our website, and we meet all 20 of the Better Business Bureau’s Standards for Charity Accountability.

STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2022 (audited)

<table>
<thead>
<tr>
<th>SUPPORT AND REVENUE</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donations and Bequests</td>
<td>$3,550,130</td>
<td>$3,509,650</td>
</tr>
<tr>
<td>Special Events</td>
<td>$449,663</td>
<td>$344,330</td>
</tr>
<tr>
<td>Other Income/Reductions</td>
<td>$14,786</td>
<td>$12,916</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$(401,936)</td>
<td>$(705,460)</td>
</tr>
<tr>
<td>Change in value of charitable trusts</td>
<td>$(4,892)</td>
<td>$44,844</td>
</tr>
<tr>
<td>Conference/Forum Income</td>
<td>$504,039</td>
<td>$328,246</td>
</tr>
<tr>
<td>Assets released from restrictions</td>
<td>$(1,522,425)</td>
<td>$(1,522,425)</td>
</tr>
<tr>
<td><strong>Total Revenue, Gains, and Support</strong></td>
<td><strong>$5,639,107</strong></td>
<td><strong>$5,546,817</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Programs</td>
<td>$2,920,639</td>
<td>$2,660,348</td>
</tr>
<tr>
<td>Education Programs</td>
<td>$1,375,694</td>
<td>$1,256,203</td>
</tr>
<tr>
<td>Administration</td>
<td>$315,124</td>
<td>$199,306</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$597,193</td>
<td>$558,140</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$5,208,650</strong></td>
<td><strong>$4,673,997</strong></td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td><strong>$430,457</strong></td>
<td><strong>$872,820</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS, end of year</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenue, Gains, and Support</strong></td>
<td><strong>$5,639,107</strong></td>
<td><strong>$5,546,817</strong></td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td><strong>$5,208,650</strong></td>
<td><strong>$4,673,997</strong></td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td><strong>$430,457</strong></td>
<td><strong>$872,820</strong></td>
</tr>
<tr>
<td><strong>Net Assets, end of year</strong></td>
<td><strong>$5,192,049</strong></td>
<td><strong>$12,060,367</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVENUE</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals 92%</td>
<td>$3,568,486</td>
<td>$3,342,500</td>
</tr>
<tr>
<td>Conferences 8%</td>
<td>$12,121,035</td>
<td>$12,060,367</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$5,192,049</strong></td>
<td><strong>$12,060,367</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research 56%</td>
<td>$2,920,639</td>
<td>$2,660,348</td>
</tr>
<tr>
<td>Education 27%</td>
<td>$1,375,694</td>
<td>$1,256,203</td>
</tr>
<tr>
<td>Development 11%</td>
<td>$315,124</td>
<td>$199,306</td>
</tr>
<tr>
<td>Administrative 6%</td>
<td>$597,193</td>
<td>$558,140</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$5,208,650</strong></td>
<td><strong>$4,673,997</strong></td>
</tr>
</tbody>
</table>

STATEMENT OF FINANCIAL POSITION AS OF JUNE 30, 2022 (audited)

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$2,859,408</td>
<td>$3,298,224</td>
</tr>
<tr>
<td>Pledges and bequests receivable</td>
<td>$1,562,244</td>
<td>$874,540</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>$115,373</td>
<td>$152,075</td>
</tr>
<tr>
<td>Booklet inventory</td>
<td>$13,288</td>
<td>$27,581</td>
</tr>
<tr>
<td><strong>Total Current Assets</strong></td>
<td><strong>$4,550,313</strong></td>
<td><strong>$4,352,420</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pledges and bequests receivable (net of present value discount and current portion)</td>
<td>$1,305,302</td>
<td>$1,506,633</td>
</tr>
<tr>
<td>Assets held in trust (at market value)</td>
<td>$66,409</td>
<td>$80,564</td>
</tr>
<tr>
<td>Investments (at market value)</td>
<td>$3,673,279</td>
<td>$4,036,842</td>
</tr>
<tr>
<td>Furniture and equipment (net of depreciation)</td>
<td>$128,096</td>
<td>$47,367</td>
</tr>
<tr>
<td>Permanently restricted cash</td>
<td>$3,342,500</td>
<td>$3,342,500</td>
</tr>
<tr>
<td><strong>Total Non-current Assets</strong></td>
<td><strong>$8,515,586</strong></td>
<td><strong>$9,013,906</strong></td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$13,065,899</strong></td>
<td><strong>$13,366,326</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$154,548</td>
<td>$114,950</td>
</tr>
<tr>
<td>Trusts, distributions payable, current portion</td>
<td>$1,562,244</td>
<td>$874,540</td>
</tr>
<tr>
<td>Grants payable</td>
<td>$449,663</td>
<td>$152,075</td>
</tr>
<tr>
<td>CARES Act</td>
<td>$504,039</td>
<td>$27,581</td>
</tr>
<tr>
<td><strong>Total Current Liabilities</strong></td>
<td><strong>$2,070,904</strong></td>
<td><strong>$1,274,791</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities to trust beneficiaries (at present value discount and current portion)</td>
<td>$1,305,302</td>
<td>$1,506,633</td>
</tr>
<tr>
<td>Assets held in trust (at market value)</td>
<td>$66,409</td>
<td>$80,564</td>
</tr>
<tr>
<td>Investments (at market value)</td>
<td>$3,673,279</td>
<td>$4,036,842</td>
</tr>
<tr>
<td>Furniture and equipment (net of depreciation)</td>
<td>$128,096</td>
<td>$47,367</td>
</tr>
<tr>
<td>Permanently restricted cash</td>
<td>$3,342,500</td>
<td>$3,342,500</td>
</tr>
<tr>
<td><strong>Total Non-current Liabilities</strong></td>
<td><strong>$8,515,586</strong></td>
<td><strong>$9,013,906</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$13,065,899</strong></td>
<td><strong>$13,366,326</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVENUE</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals 92%</td>
<td>$3,550,130</td>
<td>$3,509,650</td>
</tr>
<tr>
<td>Conferences 8%</td>
<td>$1,562,244</td>
<td>$874,540</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$5,111,182</strong></td>
<td><strong>$4,352,420</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Programs</td>
<td>$2,920,639</td>
<td>$2,660,348</td>
</tr>
<tr>
<td>Education Programs</td>
<td>$1,375,694</td>
<td>$1,256,203</td>
</tr>
<tr>
<td>Administration</td>
<td>$315,124</td>
<td>$199,306</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$597,193</td>
<td>$558,140</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$5,208,650</strong></td>
<td><strong>$4,673,997</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$3,550,130</td>
<td>$3,509,650</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$1,562,244</td>
<td>$874,540</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>$3,342,500</td>
<td>$3,342,500</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$8,455,874</strong></td>
<td><strong>$8,726,694</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOTAL LIABILITIES AND NET ASSETS</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted</strong></td>
<td>$3,550,130</td>
<td>$3,509,650</td>
</tr>
<tr>
<td><strong>Temporarily restricted</strong></td>
<td>$1,562,244</td>
<td>$874,540</td>
</tr>
<tr>
<td><strong>Permanently restricted</strong></td>
<td>$3,342,500</td>
<td>$3,342,500</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$8,455,874</strong></td>
<td><strong>$8,726,694</strong></td>
</tr>
</tbody>
</table>
One of today’s most confounding medical challenges is how to prevent and cure diseases like glaucoma, Alzheimer’s, Parkinson’s, and ALS, which occur when key central nervous system cells deteriorate and die. Launched in July 2022, the fourth Catalyst for a Cure comprises four exceptional and diversely talented young investigators. Trailblazers, pioneers, superstars in their chosen fields — all demonstrate creativity, a track record for innovative impact, a talent for collaboration, and a deep love of science. They will explore similarities and differences among glaucoma and other conditions that result from neurodegeneration in the eye, brain, or spinal cord, in search of potential preventive measures and cures.

Restoring vision in patients with glaucoma is a tremendous challenge. Because the optic nerve cannot regenerate itself naturally after injury, scientists must find innovative ways to regrow or replace retinal ganglion cells and axons. Since 2019, the CFC3 research team has made great strides toward this goal. One strategy is to derive new optic nerve cells from stem cells and transplant them into the eye. In the past, this approach has been hampered by the poor survival of transplanted cells. However, recently the team has been testing new optic nerve regeneration strategies in the laboratory, with promising preliminary results.
Promising discoveries continue to emerge from our vision restoration consortium, with dramatic progress in two areas: therapies to transplant retinal ganglion cells and ways to preserve and enhance the eye’s neurological connections. Using various glaucoma models, researchers are refining their approaches to retinal ganglion cell transplantation and identifying ways to improve cell survival. Each step moves them closer to therapeutic approaches that, ultimately, can be tested in clinical trials.

How confident are you that vision restoration will be possible?

"I am very optimistic. Science is now progressing at a rate that we’ve never seen before, with new discoveries every day. What we’re trying to achieve is seen before, with new discoveries every day. What we’re trying to achieve is quite remarkable. It will take a lot of time and effort, but I’m hopeful that we will be able to restore vision in the future."

— Yang Hu, MD, PhD

How will CFC3 help people with glaucoma?

"Both glaucoma and Alzheimer’s occur when key cells in the central nervous system deteriorate and die. By exploring what those diseases have in common, our team aims to speed discoveries that could lead to new treatments, preventive measures, and cures for all neurodegenerative conditions."

— Milica Margeta, MD, PhD

What is your perspective as a glaucoma researcher who also treats patients?

"As a computational biologist, I develop strategies and systems that make it possible to analyze vast quantities of complex data. I’m interested in developing computational approaches, rooted in machine learning, that can guide experiments and reveal complex disease mechanisms."

— Humsa Venkatesh, PhD

What are the initial goals of the Neurodegeneration Initiative?

"This consortium brings together investigators whose expertise includes neuroscience, glial cell responses, vascular interconnections, and the nervous system’s role in disease progression. During the first stage of our collaboration, we hope to identify the most promising avenues for exploration."

— Karthik Shekhar, PhD

How will CFC4 help people with glaucoma?

"I hope my findings will one day lead to novel neuroprotective treatments for all neurodegenerative illnesses."

— Anna La Torre, PhD

What are the initial goals of the Neurodegeneration Initiative?

"Their initial priority is to explore similarities and differences among glaucoma and other neurodegenerative conditions in search of potential cures. Their initial priority is to identify promising avenues of exploration, drawn from their areas of expertise, that could reveal new and why researchers.

How confident are you that vision restoration will be possible?

"I am very optimistic. Science is now progressing at a rate that we’ve never seen before, with new discoveries every day. What we’re trying to achieve is quite remarkable. It will take a lot of time and effort, but I’m hopeful that we will be able to restore vision in the future."

— Yang Hu, MD, PhD

How will CFC3 help people with glaucoma?

"Both glaucoma and Alzheimer’s occur when key cells in the central nervous system deteriorate and die. By exploring what those diseases have in common, our team aims to speed discoveries that could lead to new treatments, preventive measures, and cures for all neurodegenerative conditions."

— Milica Margeta, MD, PhD

What is your perspective as a glaucoma researcher who also treats patients?

"As a computational biologist, I develop strategies and systems that make it possible to analyze vast quantities of complex data. I’m interested in developing computational approaches, rooted in machine learning, that can guide experiments and reveal complex disease mechanisms."

— Humsa Venkatesh, PhD

What are the initial goals of the Neurodegeneration Initiative?

"This consortium brings together investigators whose expertise includes neuroscience, glial cell responses, vascular interconnections, and the nervous system’s role in disease progression. During the first stage of our collaboration, we hope to identify the most promising avenues for exploration."

— Karthik Shekhar, PhD

How will CFC4 help people with glaucoma?

"I hope my findings will one day lead to novel neuroprotective treatments for all neurodegenerative illnesses."

— Anna La Torre, PhD

What are the initial goals of the Neurodegeneration Initiative?

"Their initial priority is to explore similarities and differences among glaucoma and other neurodegenerative conditions in search of potential cures. Their initial priority is to identify promising avenues of exploration, drawn from their areas of expertise, that could reveal new and why researchers.
We express our deepest appreciation to all our donors. Each gift makes a difference and assists us with forwarding our important mission to cure glaucoma and restore vision through innovative research.

Sponsors
$5,000 to $9,999
Delta Gamma Foundation
Everalde Life Insurance Company
Eyesonics, Inc.
JIRM Foundation
MyEyes
Neighbor To Nation
Nico, S.A.
Nidek, Inc.
Trial Runners

President's Club
$1,000 to $4,999
AmazonSmile Foundation
Ameriprise Financial
Apple Matching Gifts
Applied Materials
Bank of America Matching Gifts
Caterpillar Foundation
Charities Aid Foundation of America
Community Fdn far the Fox Valley Region
Covariant Careers, Inc./Eye On Eyecare
GE Foundation
Google Gift Matching Program
Jackson State Partners Foundation
K. Arakelian Foundation
Market Scope, LLC
Mega Hertz
Microsoft Matching Gifts Program
MicroSurgical Technology
Munich Surgical Imaging GmbH
Society Of The Transfiguration
St. Louis Trust & Family Office
State Farm Companies Foundation
United Way of the Bay Area
Vanguard Matching Gift Program

Visionaries
$200,000 to $999,999
Melza M. and Frank Theodore Barr Foundation, Inc.
Estate of John A. Goffette
Estate of Audrie J. Seibel

Benefactors
$100,000 to $199,999
Paul S. May Trust
Ivy M. Pang
William W. and Verona S. Shealy Trust

Founders
$50,000 to $99,999
Dorothy A. Doscher Trust
Nancy and Patrick Forster
Renee L. Gallermaert
PM - Chang Family Charitable Trust
Rubin Obizptaten Family Foundation
Estate of Bernice Selcow
Tania W. and Michael Stepanian

Pacesetters
$25,000 to $49,999
Estate of William Black
Birdie and Bob Feldman
Nancy and Ronald Feldman, MD
Margaret and Russell Gavin
Megan Hailer and Peter Rice
Lawrence E. and Iris C. Lerner Family Charitable Fund
Eleanor McIntosh Trust
Dhun Mehta
Mellam Family Foundation
Charlotte Louise Petty
Molly and David E.I. Pyott
Estate of Michael Lewis Ream
Gary and Linda Sirk
Mano and Edward Zander & Moni & Edward Zander Family Foundation

Patrons
$10,000 to $24,999
Lari and Allen Bosch
Frederick H. and Cynthia L. Brinkman
Sarah W. and Bill Brown
Wallace and Thomas M. Brunner

CATHRAL CIRCLE
$5,000 to $9,999
Arlene Anthony and Thomas Bradshaw
Joseph Auth and Jennifer I. Yuan
Alby Perr Baker and Thomas Baker
Barsh Family Foundation
Rettig and Michele Benedict
Paula and Paul G. Chaney
Dr. Emmett Cunningham Jr., and Sharon Shaw
Mary Jane Elmore
Ken Goldman
Teri and Andy Goodman
Adrienne L. Graves, PhD
Nancy M. Graydon
Stanley R. Jones
Dan Joraanstad and Robert Herrman
Roberta R.W. Kameda
Youngsun Kwon
Stephen Lanset
Jane M. Lay

CITY FOUNDATIONS

INDIVIDUALS, ESTATES, AND FAMILY FOUNDATIONS

INDIVIDUALS

IN APPRECIATION

The following is a listing of contributors of $1,000 or more from July 1, 2021 to June 30, 2022.

CORPORATIONS AND FOUNDATIONS

Founders
$50,000 to $199,999
AbbVie Foundation
Akron Laboratories, Inc.
Cure Glaucoma Foundation
Edward Joseph Daly Foundation
Santer, Inc.
Pacesetters
$25,000 to $49,999
Allegan, Inc.
Baush & Lomb
Carl Zeiss Meditec, Inc.

Patrons
$10,000 to $24,999
Abbie Employee Engagement Fund
Ace Vision Group
Aerie Pharmaceuticals, Inc.
Applied Materials
Caro Young Brooke Foundation
Colorado Optometric Glaucoma Society, Inc.
Caterpillar Foundation

INDIVIDUALS, ESTATES, AND FAMILY FOUNDATIONS

PRESIDENT’S CIRCLE

Cornerstone
$1,000,000+
Charles and Dennis E. Singleton

Visionaries
$200,000 to $999,999
Melza M. and Frank Theodore Barr Foundation, Inc.
Estate of John A. Goffette
Estate of Audrie J. Seibel

Benefactors
$100,000 to $199,999
Paul S. May Trust
Ivy M. Pang
William W. and Verona S. Shealy Trust

Founders
$50,000 to $99,999
Dorothy A. Doscher Trust
Nancy and Patrick Forster
Renee L. Gallermaert
PM - Chang Family Charitable Trust
Rubin Obizptaten Family Foundation
Estate of Bernice Selcow
Tania W. and Michael Stepanian

Pacesetters
$25,000 to $49,999
Estate of William Black
Birdie and Bob Feldman
Nancy and Ronald Feldman, MD
Margaret and Russell Gavin
Megan Hailer and Peter Rice
Lawrence E. and Iris C. Lerner Family Charitable Fund
Eleanor McIntosh Trust
Dhun Mehta
Mellam Family Foundation
Charlotte Louise Petty
Molly and David E.I. Pyott
Estate of Michael Lewis Ream
Gary and Linda Sirk
Mano and Edward Zander & Moni & Edward Zander Family Foundation

Patrons
$10,000 to $24,999
Lari and Allen Bosch
Frederick H. and Cynthia L. Brinkman
Sarah W. and Bill Brown
Wallace and Thomas M. Brunner

Jill and Michael Chimura
Robert H. & Teni L. Cohen Family Foundation
Nancy and Henry Dehorne
James and Roberta Farrington
Margaret Funkel
Frank and Joseph Gia Fund
John W. Goings
William P. and Barbara Griffin
Leonard Gugik
Elizabeth Henn & Margaret Rigby Memorial Fund
Armin and Esther Hirsch Foundation
Andrew G. Inch, MD
Gail and Fred Kittler
Davis and Kuske Family Fund
Kathryn Mayer
Lamaree Mizio
Polly G. Nicely, MD
Barbara and Emery G. Ollcott
Denise and Sam R. Polakov
The Pammel Family Fund
Janet and Cary R. Raymond
Angelena J. Sakalay
Rhet and Xin Schiffman Charitable Fund
Nancy T. Schubert Memorial Fund
Frank and Paula Schultz
Sorja W. Schuler
The Simon/Woody Family Foundation
Ruth D. Williams, MD
and...
This honor roll is composed of contributors of $1,000 or more from July 1, 2021 to June 30, 2022. If your name has been omitted or there is an error in the listing, please notify us at 415-986-3162 ext. 231.

THE BLANCHE MATTHIAS SOCIETY

The Blanche Matthias Society recognizes those individuals who have included Glaucoma Research Foundation in their estate plans. We are grateful to the following individuals that have notified us of their intent to include us as a beneficiary in their wills, trusts, or other investment vehicles.


Visit our website at glaucoma.org/legacy or contact us at 415-986-3162.